Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current pharmaceutical design

• Publication date

  2012-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1381612811306050883PMID 22973957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

  2012cited by this paper
• Tie1 deficiency induces endothelial–mesenchymal transition

  2012cited by this paper
• Small molecule inhibitors of BRAF in clinical trials.

  2012cited by this paper
• Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

  2012cited by this paper
• The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

  2012cited by this paper
• BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

  2012cited by this paper
• Intra-tumour heterogeneity: a looking glass for cancer?

  2012cited by this paper
• Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Genetic insight and therapeutic targets in squamous-cell lung cancer

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Specifically targeting ERK1 or ERK2 kills Melanoma cells

  2012cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.

  2011cited by this paper
• Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway

  2011cited by this paper
• ERK mediates anti-apoptotic effect through phosphorylation and cytoplasmic localization of p21Waf1/Cip1/Sdi in response to DNA damage in normal human embryonic fibroblast (HEF) cells

  2011cited by this paper
• Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation.

  2011cited by this paper
• Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

  2011cited by this paper
• Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile

  2011cited by this paper
• KRAS and BRAF: drug targets and predictive biomarkers

  2011cited by this paper
• ERK5 signalling in prostate cancer promotes an invasive phenotype

  2011cited by this paper
• Cyclophosphamide‐induced apoptosis in A431 cells is inhibited by fucosyltransferase IV

  2011cited by this paper
• Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells

  2011cited by this paper
• Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

  2011cited by this paper
• MEK‐ERK Signaling Dictates DNA‐Repair Gene MGMT Expression and Temozolomide Resistance of Stem‐Like Glioblastoma Cells via the MDM2‐p53 Axis

  2011cited by this paper
• Bim Protein Degradation Contributes to Cisplatin Resistance*

  2011cited by this paper
• Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells

  2011cited by this paper
• Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

  2011cited by this paper
• Dual-specificity MAP kinase phosphatases as targets of cancer treatment.

  2011cited by this paper
• Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

  2011cited by this paper
• In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

  2011cited by this paper
• Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

  2011cited by this paper
• Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance

  2011cited by this paper
• Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.

  2011cited by this paper
• Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

  2011cited by this paper
• ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease

  2011cited by this paper
• ERK/MAPK Is Essential for Endogenous Neuroprotection in SCN2.2 Cells

  2011cited by this paper
• Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy

  2011cited by this paper
• Regulation of endonuclease activity in human nucleotide excision repair.

  2011cited by this paper
• Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells.

  2011cited by this paper
• Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD.

  2011cited by this paper
• Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.

  2011cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non–Small-Cell Lung Cancer Cells

  2010cited by this paper
• The ABC of glycosylation

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

  2010cited by this paper
• RAF protein-serine/threonine kinases: structure and regulation.

  2010cited by this paper
• CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy

  2010cited by this paper
• Expression and functional role of negative signalling regulators in tumour development and progression

  2010cited by this paper
• Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs

  2010cited by this paper
• Modulation of cell sensitivity to antitumor agents by targeting survival pathways.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• MEK1 and AKT2 Mutations in Japanese Lung Cancer

  2010cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases

  2009cited by this paper
• MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

  2009cited by this paper
• Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.

  2008cited by this paper
• Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells.

  2008cited by this paper
• Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway

  2008cited by this paper
• PUMA, a potent killer with or without p53

  2008cited by this paper
• Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

  2008cited by this paper
• MAP kinase: it's been longer than fifteen minutes.

  2008cited by this paper
• Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds

  2008cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

  2007cited by this paper
• Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance.

  2007cited by this paper
• Cancer stem cells: models and concepts.

  2007cited by this paper
• Clinical experience of MEK inhibitors in cancer therapy.

  2007cited by this paper
• Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

  2006cited by this paper
• Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Specific Inactivation and Nuclear Anchoring of Extracellular Signal-Regulated Kinase 2 by the Inducible Dual-Specificity Protein Phosphatase DUSP5

  2005cited by this paper
• A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.

  2005cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005cited by this paper
• BRAFE600-associated senescence-like cell cycle arrest of human naevi

  2005cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Both Nuclear-Cytoplasmic Shuttling of the Dual Specificity Phosphatase MKP-3 and Its Ability to Anchor MAP Kinase in the Cytoplasm Are Mediated by a Conserved Nuclear Export Signal*

  2004cited by this paper
• Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis.

  2004cited by this paper
• Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP

  2004cited by this paper
• Leukocyte-specific protein 1 targets the ERK/MAP kinase scaffold protein KSR and MEK1 and ERK2 to the actin cytoskeleton

  2004cited by this paper
• Sef is a spatial regulator for Ras/MAP kinase signaling.

  2004cited by this paper
• Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• IQGAP1 Binds Rap1 and Modulates Its Activity*

  2004cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• Epidermal Growth Factor and Ionizing Radiation Up-regulate the DNA Repair Genes XRCC1 and ERCC1 in DU145 and LNCaP Prostate Carcinoma through MAPK Signaling

  2003cited by this paper
• A Bipartite Mechanism for ERK2 Recognition by Its Cognate Regulators and Substrates*

  2003cited by this paper
• Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.

  2003cited by this paper

• PSMC6 regulation of ovarian cancer cisplatin resistance unravels a new mode for proteasome targeting

  2025cites this paper
• Targeting neurochemical and immune dysregulation in schizophrenia: From molecular mechanisms to emerging therapeutic strategies.

  2025cites this paper
• Precision Drug Repurposing

  2024cites this paper
• KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells

  2024cites this paper
• Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis

  2024cites this paper
• Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity.

  2023cites this paper
• Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?

  2023cites this paper
• Research on the effect and underlying molecular mechanism of Cangzhu in the treatment of gouty arthritis.

  2022cites this paper
• Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

  2022cites this paper
• U0126: Not only a MAPK kinase inhibitor

  2022cites this paper
• The MAPKinase Signaling and the Stimulatory Protein-1 (Sp1) Transcription Factor Are Involved in the Phototherapy Effect on Cytokines Secretion from Human Bronchial Epithelial Cells Stimulated with Cigarette Smoke Extract

  2021cites this paper
• Pathology and Molecular Mechanisms of Perineural Spread of Tumors

  2021cites this paper
• Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells

  2020cites this paper
• The rediscovery of platinum-based cancer therapy

  2020cites this paper
• SD0006 promotes nucleus pulposus cell proliferation via the p38MAPK/HDAC4 pathway.

  2020cites this paper
• The rediscovery of platinum-based cancer therapy

  2020cites this paper
• MicroRNAs as regulators of ERK/MAPK pathway: A comprehensive review.

  2020cites this paper
• Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway

  2020cites this paper
• Evaluating the role of microRNAs alterations in oral squamous cell carcinoma.

  2020cites this paper
• Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway

  2020cites this paper
• Ruthenium Complexes Containing Heterocyclic Thioamidates Trigger Caspase-Mediated Apoptosis Through MAPK Signaling in Human Hepatocellular Carcinoma Cells

  2019cites this paper
• Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche.

  2019cites this paper
• KiSS1 in regulation of metastasis and response to antitumor drugs.

  2019cites this paper
• Simiao Pill Attenuates Collagen-Induced Arthritis in Rats through Suppressing the ATX-LPA and MAPK Signalling Pathways

  2019cites this paper
• Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

  2019cites this paper
• The in vitro and in vivo anticancer effect of β-2-himachalen-6-ol isolated from the Lebanese Daucus carota spp. carota

  2019cites this paper
• Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer

  2019cites this paper
• Ginsenoside Rh1 inhibits colorectal cancer cell migration and invasion in vitro and tumor growth in vivo

  2019influential citation
• Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

  2019cites this paper
• Site-specific polyubiquitination differentially regulates parathyroid hormone receptor–initiated MAPK signaling and cell proliferation

  2018cites this paper
• Calcitonin gene-related peptide promotes proliferation and inhibits apoptosis in endothelial progenitor cells via inhibiting MAPK signaling

  2018cites this paper
• Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells

  2018influential citation
• TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway

  2017cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

  2017cites this paper
• Potential Involvement of the IL-6/JAK/STAT3 Pathway in the Pathogenesis of Intervertebral Disc Degeneration

  2017cites this paper
• Mitogen-activated protein kinase signaling pathway in oral cancer.

  2017cites this paper
• Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells

  2016cites this paper
• Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.

  2016cites this paper
• MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia

  2016cites this paper
• Cytotoxicity of Salvia miltiorrhiza Against Multidrug-Resistant Cancer Cells.

  2016cites this paper
• Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells

  2016influential citation
• Diversity and implication of MAPK signal transduction involved in the regulation of chemotherapy-induced DNA damage response

  2016cites this paper
• Chemokine-Like Receptor 1 Regulates the Proliferation and Migration of Vascular Smooth Muscle Cells

  2016cites this paper
• PTN signaling: Components and mechanistic insights in human ovarian cancer

  2015cites this paper
• Silymarin Attenuates Airway Inflammation Induced by Cigarette Smoke in Mice

  2015cites this paper
• Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)

  2015cites this paper
• EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy

  2015cites this paper
• FOR DOCTORAL DEGREE ( Ph . D . )

  2015cites this paper
• Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy

  2015cites this paper
• Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System

  2014influential citation
• Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals

  2014influential citation
• A New 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) Derivative Overcomes Paclitaxel Resistance by Inhibiting MAPK Signaling and Increasing Paclitaxel Accumulation in Breast Cancer Cells

  2014cites this paper
• Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model.

  2014cites this paper
• NF-κB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro.

  2014cites this paper
• Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.

  2014cites this paper
• Differential outcome of MEK 1 / 2 inhibitor-platinum combinations in platinum-sensitive and-resistant ovarian carcinoma cells

  2014cites this paper
• The MAPK pathway across different malignancies: A new perspective

  2014cites this paper
• Quantitative chemical and phosphoproteomics for studying signaling in cancer

  2013influential citation
• Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer.

  2012cites this paper